I continue to be underwhelmed by nintedanib, esp in RA-ILD Data from INBUILD-ON, f/u study to the INBUILD basket trial Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD? Need H2H vs TNFs & real DMARDs @RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67

Real-World Issues in AxSpA: Treatment Intensification, Pregnancy Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity. https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv

• Real-World Issues in AxSpA: Treatment Intensification, Pregnancy | RheumNow

MANDARA phase 3 RCT Benralizumab vs Mepolizumab in relapsing/refractory EGPA receiving SOC. Non-inferiority met. Abstr#L14 #ACR23 @RheumNow https://t.co/UnpF3RDHMa https://t.co/076SeynJx3

Prelim data supports further evaluation of YTB323 in srSLE. #ACR23 Abs L13 reviews safety, CAR-T cell expansion, B cell depletion and initial efficacy in 1st 3 pts. https://t.co/aOLMhBBjgY @rheumnow https://t.co/2BoNeMe3Tg

Phase 2 RCT. Selective JAK1i LNK01001 in RA. 156 patients, 24 week (12 week PBO controlled). Abstr#L09 #ACR23 @RheumNow https://t.co/hHjL1yFH0H https://t.co/Qls4zRrRGH

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

The Fallacy of Biologic Treatment to Prevent RA It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23 https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3

• The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis | RheumNow

RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/tc6S3fysL3

• SPONDYLOARTHRITIS (SpA) PATIENTS (PsA, AS, and nr-axSpA) | RheumNow

ICYMI - Nice blog! Choice Overload (and the Way Out) https://t.co/dBfgUadEd2 @rheumnow

• Choice Overload (and the Way Out) | RheumNow

Summary of diet effects in RA and SLE patients 👇 Dr. Sarah Patterson also shared nutrition resources for pts and clinicians https://t.co/ae6nLrLXca #ACR23 @Rheumnow @rheumarhyme @GerRheumDoc @doktora_ging https://t.co/8HhCHCTGLh

TM13 @ #ACR23 64 yo F w/ CHF p/w dyspnea, palpitat, chest tight EKG: monomorph VT - Prior EKG: intervent conduct delay, LAD TTE: ant wall abn, EF 35-40% LHC: LV aneurysm, nonobst CAD cMRI: abn LV wall thickening PET: hypermetab LV Endomyo Bx: necrot granuloma DX? @RheumNow

Gender differences in switching biologics in PsA pts Women had higher biologic switch rates, mainly due to lack of efficacy Other gender specific factors include gestational reasons and different sociodemographic features @RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw

I got a chance to interview first author Jun Chu @nihrheumatology for her study on GnRHa Reducing Premature Ovarian Insufficiency in SLE pts on CYP. Watch here @RheumNow #ACR23 https://t.co/VCvAiRs4ni

Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM

Dx: Necrotizing Sarcoid Granulomatosis (NSG) ➡️rare dz entitiy ➡️common features: cough, F, dyspnea, CP, or wt loss ➡️Bx can be necrot or non-necrot granulmoas ➡️Ddx: TB, GPA #ACR23 @RheumNow https://t.co/zBGVriB8ka